Related Experiment Video
Updated: Dec 19, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.2K
A comparison between warfarin and apixaban: A patient's perspective
Abdullah U Althemery1, Abdullah A Alfaifi1, Abdulrahman Alturaiki2,3,4
1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Annals of Thoracic Medicine
|June 4, 2020
Summary
Patients using warfarin reported a better quality of life than those on apixaban. Further research is needed to understand the lower quality of life scores in apixaban patients.
Area of Science:
- Pharmacology
- Patient-Reported Outcomes
- Clinical Medicine
Background:
- Novel oral anticoagulants (NOACs) offer alternatives to warfarin.
- Patient preferences for warfarin versus NOACs remain underexplored.
- Quality-of-life (QOL) surveys assess patient treatment preferences.
Purpose of the Study:
- Compare patient perspectives on warfarin versus apixaban.
- Utilize QOL measures to evaluate treatment satisfaction.
- Investigate patient-centered outcomes in anticoagulant therapy.
Main Methods:
- Cross-sectional study design in Riyadh, Saudi Arabia (2019).
- Propensity score matching to control for confounding variables.
- Descriptive statistics and greedy matching for QOL analysis.
Main Results:
- 124 matched patients (62 warfarin, 62 apixaban).
- Warfarin users reported significantly better health states (M=69.64) than apixaban users (M=66.33).
- Sociodemographic analysis revealed predominantly female, married, educated, non-smoking patients.
Conclusions:
- Warfarin users demonstrated superior QOL compared to apixaban users.
- Investigate reasons for lower QOL in apixaban patients.
- Enhance healthcare provider awareness regarding QOL in anticoagulant therapy.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
01:29Venous Thrombosis III: Interprofessional Care
203
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
203
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
941
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
941
01:30Venous Thrombosis IV: Nursing Management
141
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
141
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
234
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
234